Regeneron says antibody cocktail boosts survival of hospitalized COVID-19 patients


Regeneron's COVID-19 antibody cocktail, casirivimab and imdevimab, reduced the risk of death among hospitalized patients in a phase 3 trial, the drugmaker said June 16.

The trial found that adding 8,000 milligrams of the antibody cocktail to usual care reduced the risk of death by 20 percent in hospitalized COVID-19 patients who had not mounted their own immune response against the virus.

The FDA granted emergency use authorization to the antibody cocktail in November. Regeneron said it will discuss the new data with regulatory authorities immediately and request the treatment's FDA emergency use authorization be expanded to include appropriate hospitalized patients.


© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars